Target of rapamycin signaling in leukemia and lymphoma.

  • Vu C
  • Fruman D
  • 9


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Growth factors and many oncogenes activate the lipid kinase phosphoinositide 3-kinase (PI3K), initiating a signaling cascade that includes the protein kinases AKT and target of rapamycin (TOR). The PI3K/AKT/TOR signaling pathway is a significant contributor to disease in various human cancers, including hematologic malignancies. Here we discuss different strategies to inhibit TOR for the treatment of leukemia, lymphoma, and myeloma. The TOR enzyme exists in two complexes in cells, TORC1 and TORC2. The majority of preclinical and clinical efforts to target TOR have involved using rapamycin and its analogs (rapalogs), which suppress TORC1 only partially and do not acutely inhibit TORC2. A new class of small molecules targeting the ATP-binding site of the TOR kinase, termed active-site TOR inhibitors (asTORi), achieves greater inhibition of both TOR complexes, resulting in broader suppression of the PI3K/AKT/TOR signaling network. Preclinical evidence suggests that asTORi have greater efficacy than rapalogs in Philadelphia chromosome-positive acute lymphoblastic leukemia and in T-cell lymphoma. These agents also show greater tolerability in animal models relative to rapalogs or inhibitors of PI3K. These findings encourage broader evaluation of asTORi efficacy in acute myeloid leukemia, B-cell lymphoma, myeloma, and other blood cancers.

Author-supplied keywords

  • Animals
  • Humans
  • Leukemia
  • Leukemia: drug therapy
  • Leukemia: enzymology
  • Leukemia: metabolism
  • Lymphoma
  • Lymphoma: drug therapy
  • Lymphoma: enzymology
  • Lymphoma: metabolism
  • Phosphatidylinositol 3-Kinases
  • Phosphatidylinositol 3-Kinases: metabolism
  • Protein Kinase Inhibitors
  • Protein Kinase Inhibitors: pharmacology
  • Proto-Oncogene Proteins c-akt
  • Proto-Oncogene Proteins c-akt: metabolism
  • Signal Transduction
  • Signal Transduction: drug effects
  • TOR Serine-Threonine Kinases
  • TOR Serine-Threonine Kinases: antagonists & inhibi
  • TOR Serine-Threonine Kinases: chemistry
  • TOR Serine-Threonine Kinases: metabolism
  • Transcription Factors
  • Transcription Factors: metabolism

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Collin Vu

  • David a Fruman

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free